[1] SINGH S, RAGHAVAN B, GEETHAPRIYA S, et al. PET-CT upstaging of unilateral operable breast cancer and its correlation with molecular subtypes[J]. Indian J Radiol Imaging, 2020, 30(3): 319. doi: 10.4103/ijri.IJRI_59_20
[2] PAYDARY K, SERAJ SM, ZADEH MZ, et al. The evolving role of FDG-PET/CT in the diagnosis, staging, and treatment of breast cancer[J]. Mol Imaging Biol, 2019, 21(1): 1. doi: 10.1007/s11307-018-1181-3
[3] 胡永全, 袁超, 陶新全, 等. 18F-FDG PET/CT检测卵巢癌术后CA125升高病人转移或复发的临床分析[J]. 蚌埠医学院学报, 2020, 45(9): 1163.
[4] 母予馨, 张频, 马飞, 等. 乳腺癌原发灶和转移灶受体表达的异质性及其临床意义[J]. 中华肿瘤杂志, 2018, 40(7): 506. doi: 10.3760/cma.j.issn.0253-3766.2018.07.005
[5] 汤泊, 张银, 周锦, 等. 18F-FDG PET-CT代谢参数与乳腺癌临床病理特征的关系[J]. 中华肿瘤杂志, 2017, 39(4): 280. doi: 10.3760/cma.j.issn.0253-3766.2017.04.008
[6] 鲁胜男, 冯彦林, 李雯, 等. 局部晚期乳腺癌18F-FDG PET/CT显像和分子分型与预后相关性研究[J]. 中华肿瘤防治杂志, 2019, 26(5): 324.
[7] GARCIA-VICENTE AM, PÉREZ-BETETA J, PÉREZ-GARCÍA VM, et al. Metabolic tumor burden assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer: relation with tumor biology[J]. Mol Imaging Biol, 2017, 19(4): 636. doi: 10.1007/s11307-016-1034-x
[8] QU YH, LONG N, RAN C, et al. The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer[J]. Clin Transl Oncol, 2021, 23(3): 620. doi: 10.1007/s12094-020-02457-w
[9] 牛增志. 乳腺癌原发灶18F-FDG PET-CT代谢参数与患者临床病理特征的关系研究[J]. 中国CT与MRI杂志, 2019, 17(4): 79.
[10] HIGUCHI T, NISHIMUKAI A, OZAWA H, et al. Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes[J]. Breast, 2016, 30: 5. doi: 10.1016/j.breast.2016.08.003
[11] 李艳, 代永亮, 张卫善, 等. 18F-FDG PET/CT在乳腺癌诊断和分期中的应用价值[J]. 实用放射学杂志, 2019, 35(9): 1436. doi: 10.3969/j.issn.1002-1671.2019.09.014
[12] EGE AKTAS G, TAŞTEKIN E, SARIKAYA A. Assessment of biological and clinicalaggressiveness of invasive ductal breast cancer using baseline 18F-FDG PET/CT derived volumetric parameters[J]. Nucl Med Commun, 2018, 39(1): 83. doi: 10.1097/MNM.0000000000000779
[13] BORM KJ, VOPPICHLER J, DVSBERG M, et al. FDG/PET-CT-based lymph node atlas in breast cancer patients[J]. Int J Radiat Oncol Biol Phys, 2019, 103(3): 574. doi: 10.1016/j.ijrobp.2018.07.2025
[14] 阳宁静, 任静, 李吉满. 乳腺癌Ⅰ、Ⅱ组淋巴结Ki-67定性、定量表达差异及相关分析[J]. 蚌埠医学院学报, 2018, 43(9): 1125.
[15] AN YS, KANG DK, JUNG Y, et al. Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis[J]. Medicine(Baltimore), 2017, 96(45): e8557.
[16] 宋旗, 胡友庭, 杨泳, 等. 乳腺癌组织细胞核增殖抗原的异常表达与病理特征相关性[J]. 中华实验外科杂志, 2020, 37(2): 317.
[17] AN YS, KANG DK, JUNG Y, et al. Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases[J]. Surg Today, 2020, 50(7): 657. doi: 10.1007/s00595-019-01831-8
[18] 张倩, 辛军, 李红, 等. 18F-FDG PET/CT显像半定量参数MTV、TLG联合SUV在乳腺癌诊断中的应用价值[J]. 中国临床医学影像杂志, 2016, 27(9): 620.
[19] ARSLAN E, CAN TRABULUS D, MERMUT Ö, et al. Alternative volumetric PET parameters for evaluation of breast cancer cases with 18F-FDG PET/CT imaging: Metabolic tumour volume and total lesion glycolysis[J]. J Med Imaging Radiat Oncol, 2021, 65(1): 38. doi: 10.1111/1754-9485.13114
[20] ORSARIA P, CHIARAVALLOTI A, CAREDDA E, et al. Evaluation of the usefulness of FDG-PET/CT for nodal staging of breast cancer[J]. Anticancer Res, 2018, 38(12): 6639. doi: 10.21873/anticanres.13031